STOCK TITAN
  1. Home
  2. Sec-filings
  3. MAZE
  4. [Form 4] Maze Therapeutics, Inc. Insider Trading Activity

Maze Therapeutics (MAZE) CMO sells 15,000 shares, exercises options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Maze Therapeutics, Inc. President, R&D & CMO Harold Bernstein reported an exercise-and-sell transaction in Common Stock. On May 14, 2026, he exercised stock options to acquire 15,000 shares at $10.42 per share, then sold the same 15,000 shares in open-market transactions at a weighted average price of $26.2236 per share, with individual sale prices ranging from $25.77 to $26.44. These trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on September 29, 2025. After the sale, he reported holding no Common Stock directly, while retaining 222,407 stock options with a $10.42 exercise price expiring on October 26, 2032.

Positive

  • None.

Negative

  • None.
Insider Bernstein Harold
Role President, R&D & CMO
Sold 15,000 shs ($393K)
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) 15,000 $0.00 --
Exercise Common Stock 15,000 $10.42 $156K
Sale Common Stock 15,000 $26.2236 $393K
Holdings After Transaction: Stock Option (Right to Buy) — 222,407 shares (Direct, null); Common Stock — 15,000 shares (Direct, null)
Footnotes (1)
  1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.77 to $26.44 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
Shares sold 15,000 shares Common Stock sold in open-market transactions on May 14, 2026
Weighted average sale price $26.2236 per share Common Stock sale price range $25.77–$26.44 on May 14, 2026
Options exercised 15,000 shares Common Stock acquired via option exercise on May 14, 2026
Option exercise price $10.42 per share Stock Option (Right to Buy) conversion price
Remaining stock options 222,407 options Stock Option (Right to Buy) position after exercise, expiring October 26, 2032
10b5-1 plan adoption date September 29, 2025 Date Harold Bernstein adopted the Rule 10b5-1 trading plan
Common shares held after sale 0 shares Directly held Common Stock following the May 14, 2026 transactions
Rule 10b5-1 trading plan regulatory
"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The reported price in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) ... underlying security title: Common Stock"
derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
vesting financial
"The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Bernstein Harold
(Last)(First)(Middle)
C/O MAZE THERAPEUTICS, INC.
171 OYSTER POINT BOULEVARD, SUITE 300
(Street)
SOUTH SAN FRANCISCO CALIFORNIA 94080
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
President, R&D & CMO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/14/2026M(1)15,000A$10.4215,000D
Common Stock05/14/2026S(1)15,000D$26.2236(2)0D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$10.4205/14/2026M(1)15,000 (3)10/26/2032Common Stock15,000$0222,407D
Explanation of Responses:
1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.77 to $26.44 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
/s/ Courtney Phillips, as attorney-in-fact05/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did MAZE executive Harold Bernstein report?

Harold Bernstein reported an exercise-and-sell transaction involving 15,000 shares of Maze Therapeutics Common Stock. He exercised options to buy 15,000 shares at $10.42, then sold those 15,000 shares in open-market trades at a weighted average price of $26.2236 per share.

At what prices did Harold Bernstein sell MAZE shares in this Form 4?

He sold 15,000 Maze Therapeutics shares at a weighted average price of $26.2236 per share. The filing notes multiple trades, with individual sale prices ranging from $25.77 to $26.44 per share, and offers regulators and holders detailed breakdowns on request.

Were Harold Bernstein’s MAZE stock sales under a Rule 10b5-1 plan?

Yes. The Form 4 states the sales were effected under a Rule 10b5-1 trading plan adopted on September 29, 2025. Such pre-arranged plans schedule trades in advance, helping separate routine portfolio management from discretionary market-timing decisions.

How many Maze Therapeutics shares did Harold Bernstein sell in this filing?

He sold 15,000 shares of Maze Therapeutics Common Stock in open-market transactions. These sales followed the exercise of stock options for the same 15,000 shares, resulting in no net increase in his directly held common share position after the reported transactions.

What stock option position does Harold Bernstein retain in MAZE after this transaction?

Following the reported transactions, he holds 222,407 stock options with a $10.42 per-share exercise price. These options relate to Maze Therapeutics Common Stock and are scheduled to expire on October 26, 2032, according to the Form 4 derivative transaction details.

What role does Harold Bernstein hold at Maze Therapeutics (MAZE)?

In this Form 4, Harold Bernstein is identified as an officer of Maze Therapeutics serving as President, R&D & CMO. The filing reports his personal transactions in Maze Therapeutics equity, including both option exercises and related open-market share sales.